ACTOVEGIN 80mg/2ml Injection/Solution for

What is ACTOVEGIN 80mg/2ml

ACTOVEGIN 80mg/2ml is a sterile injectable solution containing deproteinised hemoderivative of calf blood at a concentration of 80mg per 2ml ampoule. This medicinal product is used to enhance tissue oxygenation and support cellular metabolism, especially in conditions where impaired blood flow or metabolic dysfunction limits tissue repair and function. Derived from calf blood through a process that removes proteins, ACTOVEGIN retains biologically active molecules such as peptides, amino acids, nucleotides, and electrolytes which facilitate metabolic improvement and regeneration of damaged tissues.

Clinically, ACTOVEGIN 80mg/2ml is employed in the treatment of diseases characterized by chronic ischemia, neuropathy, delayed wound healing, and neurodegenerative disorders. Its capacity to improve microcirculation and promote cellular energy production makes it useful in both neurological and vascular pathologies. The small volume and lower concentration ampoule make it suitable for individualized dosing or use in sensitive patient populations.

• Pharmaceutical form: Injection/solution in 2ml ampoules.
• Active ingredient: Deproteinised hemoderivative of calf blood, 80mg per ampoule.
• Indicated for improving tissue oxygenation and metabolic function.
• Used in peripheral vascular diseases, diabetic neuropathy, and wound healing.

How to use ACTOVEGIN 80mg/2ml

p> ACTOVEGIN 80mg/2ml should be administered only under medical supervision. The route and frequency depend on the patient's condition and clinical judgement.

• Intravenous administration: Typically diluted in sterile isotonic saline or glucose solution and infused slowly over 30 to 60 minutes.
• Intramuscular injection: Can be given as a deep muscle injection, usually once daily.
• Inspect ampoule: Use only clear, colorless solutions free from particles. Do not use if the solution appears cloudy or contains sediment.
• Dosage frequency: Usually once or twice daily, depending on severity and response.
• Duration of therapy: Varies from 10 days to several weeks; continuation based on therapeutic outcomes.
• Precautions: Use aseptic technique to minimize infection risk. Avoid mixing with other drugs unless compatibility is confirmed.

Patient’s medical history and concurrent medications should be reviewed before initiating treatment.

Mode of Action ACTOVEGIN 80mg/2ml

The therapeutic effects of ACTOVEGIN 80mg/2ml arise from its ability to improve oxygen and glucose uptake by cells, thereby enhancing energy metabolism, which is critical for tissue repair and function in ischemic or metabolically compromised areas.

• Improves oxygen diffusion: Enhances oxygen transport through plasma and tissues, increasing oxygen availability in hypoxic zones.
• Stimulates glucose utilization: Facilitates cellular uptake and metabolism of glucose, boosting aerobic respiration and ATP production.
• Supports mitochondrial function: Provides metabolic substrates such as amino acids and nucleotides that aid mitochondrial energy production.
• Promotes tissue repair: Enhances microcirculation and angiogenesis, encouraging regeneration of nerve and muscle tissues.
• Reduces oxidative stress: May contribute to neuroprotection by mitigating free radical damage.

These combined actions make ACTOVEGIN beneficial in treating conditions with compromised blood flow, nerve damage, and chronic wounds.

ACTOVEGIN 80mg/2ml Interactions ACTOVEGIN 80mg/2ml

ACTOVEGIN has a relatively low risk of significant drug interactions, but certain considerations should be kept in mind to ensure patient safety.

• Anticoagulants and antiplatelets: No direct interaction, but improved microcirculation could affect bleeding risk, warranting monitoring.
• Hypoglycemic agents: May enhance the effect of insulin or oral antidiabetic drugs by promoting glucose uptake, requiring blood sugar monitoring.
• Vasodilators: Combined use may potentiate vasodilatory effects, possibly leading to hypotension or dizziness.
• Parenteral medications: Compatibility must be checked before mixing in the same infusion line to avoid precipitation or inactivation.
• Immunosuppressants: The risk of immune reactions is low, but caution advised if used concomitantly.

Always inform healthcare providers of all medications being taken to prevent unwanted interactions.

Dosage of ACTOVEGIN 80mg/2ml

Dosage should be individualized based on patient age, clinical condition, and therapeutic response. The typical dosing regimen is as follows:

• Adults: Usually 1 to 2 ampoules (80mg to 160mg) daily, administered intravenously or intramuscularly.
• Intravenous infusion: Slow infusion diluted in 100-250ml isotonic saline or glucose over 30-60 minutes.
• Intramuscular injection: Deep muscle injection once daily.
• Duration: Commonly 10-20 days; extension based on clinical judgment and patient improvement.
• Elderly and patients with comorbidities: May require dose adjustment and careful monitoring.
• Pediatric use: Not generally recommended due to limited safety data.

Treatment should be regularly evaluated to optimize efficacy and minimize adverse effects.

Possible side effects of ACTOVEGIN 80mg/2ml

Although generally well tolerated, ACTOVEGIN 80mg/2ml can cause some side effects, which healthcare providers should monitor.

• Local reactions: Pain, swelling, or redness at the injection site.
• Hypersensitivity: Allergic reactions such as rash, itching, urticaria, or rare anaphylactic reactions.
• Systemic symptoms: Headache, dizziness, nausea, or gastrointestinal discomfort may occur.
• Immune sensitization: Rare but possible due to the animal origin of the product.
• Others: Fever or chills suggesting immune or inflammatory response.

Serious adverse effects are uncommon, but any unexpected or severe symptoms should be promptly reported.

ACTOVEGIN 80mg/2ml Contraindications ACTOVEGIN 80mg/2ml

The use of ACTOVEGIN 80mg/2ml is contraindicated in certain clinical situations:

• Hypersensitivity: Known allergy to ACTOVEGIN or any of its components.
• Active infections: Use caution in systemic infections as metabolic stimulation could exacerbate these conditions.
• Severe hepatic or renal impairment: Safety data are insufficient, so use is not recommended unless clearly justified.
• Pregnancy and lactation: Lack of conclusive safety data; avoid unless benefits outweigh risks.
• Pediatric patients: Insufficient safety evidence to recommend routine use.

Comprehensive medical assessment is essential before initiating treatment.

Storage of ACTOVEGIN 80mg/2ml

Proper storage ensures the stability and effectiveness of ACTOVEGIN 80mg/2ml injection:

• Temperature: Store refrigerated between 2°C and 8°C. Do not freeze.
• Light protection: Keep ampoules in original packaging to avoid light exposure.
• Aseptic handling: Use sterile technique when opening ampoules.
• Expiration: Do not use after the expiration date stated on the packaging.
• Disposal: Dispose of unused or expired medication safely according to local regulations.

Following these guidelines preserves the drug's efficacy and patient safety.